|
|
Article: ZIOPHARM and The University of Texas M.D. Anderson Cancer Center Present Data on ZIO-102 at American Society of Hematology; Second Organic Arsenic.
- Article from:
- PR Newswire
- Article date:
- December 6, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, DEC. 6 /PRNewswire/ -- ZIOPHARM, Inc. today announced that Dr. Xiaodong Cheng, MD from The University of Texas M.D. Anderson Cancer Center presented preclinical data on ZIO-102, the second of the Company's organic arsenic products. Data were presented at the 46th Annual Meeting of the American Society of Hematology (ASH), December 3-8, in San Diego. In studies that compared ZIO-102, a lipid-soluble organic arsenic, to arsenic trioxide, ZIO-102 was shown to be significantly more active against several human leukemia cell lines. ZIO-102 was also considerably less toxic than arsenic trioxide in both in vivo and in vitro assays. These findings with ZIO-102 ...